{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:56:58Z","timestamp":1790827018371,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The ongoing spread of antimicrobial resistance has generated an urgent need for new antibiotics, especially against multidrug-resistant (MDR) gram-negative pathogens. Taniborbactam (previously VNRX-5133) is a novel bicyclic boronate \u03b2-lactamase inhibitor with potent, selective, and direct inhibitory activity against Ambler class A, B, C, and D enzymes, including serine and metallo-\u03b2-lactamases. Taniborbactam has a broader spectrum of inhibition than any other current \u03b2-lactamase inhibitor. The combination of cefepime with taniborbactam is in advanced clinical development. Investigators are studying the activity of cefepime-taniborbactam against gram-negative pathogens, including Enterobacterales species like carbapenem-resistant Klebsiella pneumoniae and MDR Pseudomonas aeruginosa with characterized carbapenem resistance mechanisms. In this review, we discuss the advances in medicinal chemistry that led to the development of cefepime-taniborbactam, the pharmacokinetics and pharmacodynamics, the antimicrobial spectrum of activity, potential uses in the clinic, and mechanisms of resistance. We propose future clinical scenarios to better explore the precise niche of this novel inhibitor combination.<\/jats:p>","DOI":"10.1093\/infdis\/jiaf203","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T13:01:12Z","timestamp":1747054872000},"source":"Crossref","is-referenced-by-count":7,"title":["Cefepime-Taniborbactam\u2014a Novel Combination Therapy for Multidrug-Resistant Pathogens"],"prefix":"10.1093","author":[{"given":"Richard R","family":"Watkins","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Northeast Ohio Medical University , Rootstown, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5741-7613","authenticated-orcid":false,"given":"Tracy L","family":"Lemonovich","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, MetroHealth Medical Center , Cleveland, Ohio ,","place":["USA"]},{"name":"Department of Medicine, Case Western Reserve University School of Medicine , Cleveland, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro J","family":"Vila","sequence":"additional","affiliation":[{"name":"Instituto de Biolog\u00eda Molecular y Celular de Rosario , Santa Fe, Santa Fe ,","place":["Argentina"]},{"name":"\u00c1rea Biof\u00edsica, Facultad de Ciencias Bioqu\u00edmicas y Farmac\u00e9uticas, Universidad Nacional de Rosario , Rosario, Santa Fe ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3299-894X","authenticated-orcid":false,"given":"Robert A","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Case Western Reserve University School of Medicine , Cleveland, Ohio ,","place":["USA"]},{"name":"Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine , Cleveland, Ohio ,","place":["USA"]},{"name":"Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center , Cleveland, Ohio ,","place":["USA"]},{"name":"Center for Antimicrobial Resistance and Epidemiology, Case Western Reserve University-Cleveland Veterans Affairs Medical Center , Cleveland, Ohio ,","place":["USA"]},{"name":"Department of Pharmacology, Case Western Reserve University School of Medicine , Cleveland, Ohio ,","place":["USA"]},{"name":"Department of Biochemistry, Case Western Reserve University School of Medicine , Cleveland, Ohio ,","place":["USA"]},{"name":"Department of Proteomics and Bioinformatics, Case Western Reserve University School of Medicine , Cleveland, Ohio ,","place":["USA"]},{"name":"Louis Stokes Cleveland Department of Veterans Affairs Medical Center , Cleveland, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"2025051209010816900_jiaf203-B1","author":"Centers for Disease Control and Prevention"},{"key":"2025051209010816900_jiaf203-B2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.idc.2020.04.002","article-title":"Overview: the ongoing threat of antimicrobial resistance","volume":"34","author":"Watkins","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"2025051209010816900_jiaf203-B3","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051209010816900_jiaf203-B4","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1473-3099(20)30868-9","article-title":"The urgent need for metallo-\u03b2-lactamase inhibitors: an unattended global threat","volume":"22","author":"Mojica","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025051209010816900_jiaf203-B5","first-page":"1","article-title":"Novel agents in development for the treatment of resistant gram-negative infections","volume":"26","author":"Bassetti","year":"2024","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025051209010816900_jiaf203-B6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1586\/14787210.6.6.805","article-title":"Cefepime: a reappraisal in an era of increasing antimicrobial resistance","volume":"6","author":"Endimiani","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025051209010816900_jiaf203-B7","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jac\/dkaa511","article-title":"An update on cefepime and its future role in combination with novel \u03b2-lactamase inhibitors for MDR enterobacterales and Pseudomonas aeruginosa","volume":"76","author":"Isler","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025051209010816900_jiaf203-B8","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40265-024-02082-9","article-title":"Cefepime-taniborbactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"84","author":"Zhanel","year":"2024","journal-title":"Drugs"},{"key":"2025051209010816900_jiaf203-B9","doi-asserted-by":"crossref","first-page":"8510","DOI":"10.1021\/acs.jmedchem.3c00144","article-title":"Synthesis of a novel boronic acid transition state inhibitor, MB076: a heterocyclic triazole effectively inhibits Acinetobacter-derived cephalosporinase variants with an expanded-substrate spectrum","volume":"66","author":"Powers","year":"2023","journal-title":"J Med Chem"},{"key":"2025051209010816900_jiaf203-B10","doi-asserted-by":"crossref","first-page":"107228","DOI":"10.1016\/j.bpc.2024.107228","article-title":"Metallo-\u03b2-lactamase inhibitors: a continuing challenge for combating antibiotic resistance","volume":"309","author":"Kang","year":"2024","journal-title":"Biophys Chem"},{"key":"2025051209010816900_jiaf203-B11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3390\/antibiotics12040761","article-title":"Novel antimicrobial agents for gram-negative pathogens","volume":"12","author":"Karvouniaris","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2025051209010816900_jiaf203-B12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jac\/dkac446","article-title":"In vivo pharmacokinetic\/pharmacodynamic evaluation of cefepime\/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model","volume":"78","author":"Abdelraouf","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025051209010816900_jiaf203-B13","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1021\/acs.jmedchem.9b00911","article-title":"Bicyclic boronate VNRX-5133 inhibits metallo- and serine-\u03b2-lactamases","volume":"62","author":"Krajnc","year":"2019","journal-title":"J Med Chem"},{"key":"2025051209010816900_jiaf203-B14","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1021\/acs.jmedchem.9b01518","article-title":"Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-\u03b2-lactamase inhibitor for carbapenem-resistant bacterial infections","volume":"63","author":"Liu","year":"2020","journal-title":"J Med Chem"},{"key":"2025051209010816900_jiaf203-B15","doi-asserted-by":"crossref","first-page":"e01963-19","DOI":"10.1128\/AAC.01963-19","article-title":"VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine- and metallo-\u03b2-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa","volume":"64","author":"Hamrick","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051209010816900_jiaf203-B16","doi-asserted-by":"crossref","first-page":"e0133223","DOI":"10.1128\/aac.01332-23","article-title":"Structural role of K224 in taniborbactam inhibition of NDM-1","volume":"68","author":"Ono","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051209010816900_jiaf203-B17","doi-asserted-by":"crossref","first-page":"e0151023","DOI":"10.1128\/aac.01510-23","article-title":"The metallo-\u03b2-lactamases strike back: emergence of taniborbactam escape variants","volume":"68","author":"Tamma","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051209010816900_jiaf203-B18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(23)00069-5","article-title":"NDM-9 resistance to taniborbactam","volume":"23","author":"Le Terrier","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025051209010816900_jiaf203-B19","doi-asserted-by":"crossref","first-page":"e0116823","DOI":"10.1128\/aac.01168-23","article-title":"Structural basis of metallo-\u03b2-lactamase resistance to taniborbactam","volume":"68","author":"Drusin","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051209010816900_jiaf203-B20","doi-asserted-by":"crossref","first-page":"e0099123","DOI":"10.1128\/aac.00991-23","article-title":"Relative inhibitory activities of the broad-spectrum \u03b2-lactamase inhibitor taniborbactam against metallo-\u03b2-lactamases","volume":"68","author":"Le Terrier","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051209010816900_jiaf203-B21","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01672-24","article-title":"Impact of porin deletions on cefepime-taniborbactam activity against Klebsiella pneumoniae [published online ahead of print 2 April 2025]","author":"Uehara","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051209010816900_jiaf203-B22","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-022-01137-y","article-title":"Clinical pharmacokinetics and pharmacodynamics of cefepime","volume":"61","author":"Pais","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2025051209010816900_jiaf203-B23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FTD.0000000000000675","article-title":"Meropenem, cefepime, and piperacillin protein binding in patient samples","volume":"42","author":"Al-Shaer","year":"2020","journal-title":"Ther Drug Monit"},{"issue":"Suppl B","key":"2025051209010816900_jiaf203-B24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jac\/32.suppl_B.117","article-title":"Pharmacokinetics of cefepime in patients with the sepsis syndrome","volume":"32","author":"Kieft","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"2025051209010816900_jiaf203-B25","doi-asserted-by":"crossref","first-page":"e0105321","DOI":"10.1128\/AAC.01053-21","article-title":"Safety and pharmacokinetics in human volunteers of taniborbactam (VNRX-5133), a novel intravenous \u03b2-lactamase inhibitor","volume":"65","author":"Dowell","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051209010816900_jiaf203-B26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jac\/dkac447","article-title":"Bronchopulmonary disposition of IV cefepime\/taniborbactam (2\u20130.5\u2005g) administered over 2\u2005hours in healthy adult subjects","volume":"78","author":"Asempa","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025051209010816900_jiaf203-B27","doi-asserted-by":"crossref","first-page":"e0025322","DOI":"10.1128\/aac.00253-22","article-title":"Safety and pharmacokinetics of taniborbactam (VNRX-5133) with cefepime in subjects with various degrees of renal impairment","volume":"66","author":"Dowell","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051209010816900_jiaf203-B28","doi-asserted-by":"crossref","first-page":"107304","DOI":"10.1016\/j.ijantimicag.2024.107304","article-title":"Pharmacodynamics of taniborbactam in combination with cefepime studied in an in vitro model of infection","volume":"64","author":"Noel","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2025051209010816900_jiaf203-B29","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1093\/jac\/dkaa373","article-title":"In vivo pharmacodynamics of new-generation \u03b2-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-\u03b2-lactamase-producing gram-negative bacteria","volume":"75","author":"Abdelraouf","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025051209010816900_jiaf203-B30","doi-asserted-by":"crossref","first-page":"e0128122","DOI":"10.1128\/aac.01281-22","article-title":"In vitro activity of cefepime-taniborbactam and comparators against clinical isolates of gram-negative bacilli from 2018 to 2020: results from the global evaluation of antimicrobial resistance via surveillance (GEARS) program","volume":"67","author":"Karlowsky","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051209010816900_jiaf203-B31","doi-asserted-by":"crossref","first-page":"e0161424","DOI":"10.1128\/aac.01614-24","article-title":"Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors","volume":"69","author":"Outeda-Garc\u00eda","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051209010816900_jiaf203-B32","doi-asserted-by":"crossref","first-page":"dlae060","DOI":"10.1093\/jacamr\/dlae060","article-title":"In vitro activity of cefepime\/taniborbactam and comparator agents against gram-negative bacterial bloodstream pathogens recovered from patients with cancer","volume":"6","author":"Gerges","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2025051209010816900_jiaf203-B33","doi-asserted-by":"crossref","first-page":"e0151124","DOI":"10.1128\/aac.01511-24","article-title":"Cefepime-taniborbactam and ceftibuten-ledaborbactam maintain activity against KPC variants that lead to ceftazidime-avibactam resistance","volume":"69","author":"Myers","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2025051209010816900_jiaf203-B34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jac\/dkaa391","article-title":"Activity of \u03b2-lactam\/taniborbactam (VNRX-5133) combinations against carbapenem-resistant gram-negative bacteria","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025051209010816900_jiaf203-B35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa2304748","article-title":"Cefepime-taniborbactam in complicated urinary tract infection","volume":"390","author":"Wagenlehner","year":"2024","journal-title":"N Engl J Med"},{"key":"2025051209010816900_jiaf203-B36","author":"Center for Infectious Disease Research and Policy, University of Minnesota"},{"key":"2025051209010816900_jiaf203-B37","doi-asserted-by":"crossref","first-page":"F1000 Faculty Rev-121","DOI":"10.12688\/f1000research.16517.1","article-title":"Current trends in the treatment of pneumonia due to multidrug-resistant gram-negative bacteria","volume":"8","author":"Watkins","year":"2019","journal-title":"F1000Res"},{"key":"2025051209010816900_jiaf203-B38","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10096-013-1819-7","article-title":"Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance","volume":"32","author":"Montassier","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025051209010816900_jiaf203-B39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11274-024-04209-2","article-title":"Identifying multidrug-resistant organisms in diabetic foot ulcers: a study of risk factors and antimicrobial resistance genes","volume":"41","author":"Saleem","year":"2024","journal-title":"World J Microbiol Biotechnol"},{"key":"2025051209010816900_jiaf203-B40","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1093\/cid\/ciae346","article-title":"2024 clinical practice guideline update by the Infectious Diseases Society of America on complicated intra-abdominal infections: risk assessment, diagnostic imaging, and microbiological evaluation in adults, children, and pregnant people","volume":"79","author":"Bonomo","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025051209010816900_jiaf203-B41","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/sur.2023.375","article-title":"Distribution and antimicrobial resistance of complicated intraabdominal infection pathogens in two tertiary hospitals in Egypt","volume":"25","author":"Hussein","year":"2024","journal-title":"Surg Infect (Larchmt)"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf203\/63105570\/jiaf203.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaf203\/63105570\/jiaf203.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T13:01:18Z","timestamp":1747054878000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/advance-article\/doi\/10.1093\/infdis\/jiaf203\/8126815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaf203","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"article-number":"jiaf203"}}